Follicular Lymphoma
Yescarta is the first CAR T-cell therapy approved by the FDA for patients with follicular lymphoma. It uses the patient’s own genetically modified T-cells to fight the cancer. Read More ›
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma. Read More ›
Last year, the anticancer drug Tazverik (tazemetostat) received approval for use in the treatment of 2 malignancies. Read More ›
By Pam Neff
With a demanding career and 3 small children, Pam Neff had to make some difficult decisions during her treatment for an aggressive blood cancer. Read More ›
By Erika Brooks
For Erika Brooks, it took some time to adjust to what it means to have an incurable cancer. She says, “at first, I kept thinking it was a death sentence.” Eventually, she came to see her cancer in a different light. Read More ›
By Jack Elliott
Several new treatment options were approved by the FDA for patients with follicular lymphoma. Read More ›
Here is an outline of what to expect when follicular lymphoma returns. Read More ›